Eris Lifesciences Limited
| File:Logo of Eris Lifesciences.png | |
| Public | |
| Traded as | BSE: 540596 NSE: ERIS BSE SENSEX Constituent CNX Nifty Constituent |
| ISIN | 🆔 |
| Industry | Pharmaceuticals |
| Founded 📆 | 2007 |
| Founder 👔 | Amit Bakshi |
| Headquarters 🏙️ | Mumbai, Maharashtra, India |
Area served 🗺️ | India |
Key people | Himanshu Shah, (Executive Director) Inderjeet Singh Negi, (Executive Director) |
| Products 📟 | Pharmaceuticals and diagnostics |
| Revenue🤑 |  INR Rs 929.04 Cr (2019) [1] |
| INR Rs 334.57 Cr.(2019) [2] | |
| INR Rs 896.54 Cr (2019) [3] | |
| Members | |
Number of employees | 3,266 |
| Subsidiaries | Kinedex Healthcare Pvt. Ltd. UTH Healthcare Ltd. Eris Healthcare Pvt. Ltd. (formerly known as Strides Healthcare Pvt. Ltd.) Eris Therapeutic Pvt. Ltd. Aprica Healthcare Pvt. Ltd. |
| 🌐 Website | www.eris.co.in |
| 📇 Address | |
| 📞 telephone | |
Eris Lifesciences Limited is an Indian pharmaceutical company based in Ahmedabad, Gujarat, India. Eris Lifesciences primarily produces medical products for the Indian Branded Formulations market.[1]
History[edit]
Eris Lifesciences was founded by Amit Indubhushan Bakshi and his team in 2007.[2]
In 2011, private-equity player ChrysCapital invested ₹ 160 crore ($50 million) in Eris for a 16% stake of Eris Lifesciences.[3]
2012, the company had launched the diagnostics for Vitamin D deficiency, and has eight such products in its portfolio, including suppositories.[2]
In 2017, 10 years post its launch, Eris Life Sciences made a public offer of its shares and got listed on the Bombay Stock Exchange and National Stock Exchange.[4]
Eris Lifesciences derives 66% of its revenues from the chronic segment, ranking amongst the top 20 in the cardio and anti-diabetes therapeutic groups in the Indian Pharmaceutical Market (IPM). The company owned 80 mother brand groups as of March 2017.[5] The company incurred finance costs of ₹106 million for FY 18 when compared to against INR 10 million in FY 17. This was due to the borrowings related to multiple strategic acquisitions during the year.[6]
Eris Lifesciences rank progression in the Indian Pharmaceutical Market (IPM) since its launch in 2007:[2]
| Year | Rank (Indian Pharmaceutical Market) |
| 2007 | Incorporated |
| 2008 | 123 |
| 2010 | 65 |
| 2012 | 33 |
| 2017 | 29 |
| 2019 | 24 |
On 16 July 2019, Eris Lifesciences announced the resignation of Mr Himanshu Shah, the Executive Director who was associated with the company since its inception back in 2007.[7]
Brands of Eris[edit]
Over the last year Eris Lifesciences has made four acquisitions and they have diversified into more specific therapy wise brands within the healthcare sectors which included home blood pressure monitors (HMBP) and Medical Nutrition Therapy (MNT).[8]
Source: IMS TSA and Medical Audit MAT, Mar 2018.[9][10]
Manufacturing[edit]
The Eris Lifesciences manufacturing facility spreads over 76,617.51 sq. feet built up area in Guwahati, Assam.[11]
For FY 18 and FY 17, products manufactured at the facility contributed to 65.9% and 77.9% of its revenues, respectively.[6]
The facility currently operates on a single shift basis, however it is scalable up to a maximum of three shifts per day:[12]
Tablets: 999.99
Capsules: 83.02
Sachets: 18.00
Records of the capacity utilization on single shift basis annually per million units:
| Product | FY 2016 | FY 2017 | FY 2018 | |||
| Output | Utilization | Output | Utilization | Output | Utilization | |
| Tablets | 508.4 | 50.80% | 760.5 | 76.10% | 811.7 | 81.20% |
| Capsules | 41.4 | 49.90% | 47.8 | 57.60% | 67.1 | 80.80% |
| Sachets | 3.9 | 21.40% | 3.5 | 19.60% | 1.6 | 8.70% |
The company complies with all environmental norms imposed by the authorities and follows the quality of its products will stay intact for the entire duration of the shelf life of the manufactured products, whether it is produced by themselves or its third party vendors.[6]
Distribution Network[edit]
Eris Lifesciences' distribution network consists of 2 central warehouses, 23 CFAs/ consignees and over 1950+ stockists which results in over 5,00,000 chemist outlets across the country stocking their products.[6]
References[edit]
- ↑ "Company History". Eris Lifesciences. Retrieved 2019-08-30.
- ↑ 2.0 2.1 2.2 "Eris Life Sciences: Drug Money". Forbes India. Retrieved 2019-08-22.
- ↑ "BT-YES Bank Emerging Companies - Eris Lifesciences". www.businesstoday.in. Retrieved 2019-09-21.
- ↑ "Things to know before Eris Lifesciences IPO - BACKGROUND:". The Economic Times. Retrieved 2019-09-21.
- ↑ "ERIS LIFE SCIENCES LTD". The Money Roller. 2017-06-16. Retrieved 2019-08-22.
- ↑ 6.0 6.1 6.2 6.3 "Check out the Eris lifesciences ltd Management Discussions | Live stock/Share Prices at www.indiainfoline.com". www.indiainfoline.com. Retrieved 2019-08-21.
- ↑ "Eris Lifesciences Ltd announces resignation of Mr. Himanshu Shah, Executive Director". EquityBulls. 2019-03-19. Retrieved 2019-08-22.
- ↑ Das, Sohini (2018-02-21). "How Eris is weaving a success story around its 4 distressed acquisitions". Business Standard India. Retrieved 2019-08-22.
- ↑ "Leading Brands". Eris Lifesciences. Retrieved 2019-08-22.
- ↑ "Check out the Eris lifesciences ltd Management Discussions | Live stock/Share Prices at www.indiainfoline.com". www.indiainfoline.com. Retrieved 2019-08-30.
- ↑ "Results to watch out - Sun Pharma, Tech Mahindra, Bank of Baroda". www.indiainfoline.com. Retrieved 2019-09-21.
- ↑ "Manufacturing Facility". Eris Lifesciences. Retrieved 2019-08-22.
External Links[edit]
- Official Website
- Business data for Eris.co.in, LTD.: ERIS Google Finance
- Yahoo! Finance
- Bloomberg
- Reuters
This article "Eris Lifesciences" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Eris Lifesciences. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
